Novartis

The World Health Organization (WHO) has granted prequalification to Coartem® Baby (artemether-lumefantrine), the first anti-malarial medication specifically developed by the Swiss pharmaceutical company Novartis...

A new era in the treatment of Sjögren's syndrome is beginning. The FDA has granted "Breakthrough Therapy" designation to ianalumab, a drug developed by...

The pharmaceutical company Novartis has published new data from a clinical trial (Phase III PSMAddition). According to the study, the radioligand therapy Pluvicto significantly...

The traditional model of the pharmaceutical industry focuses on developing single-use drugs. However, platform-based approaches are gaining ground in modern medicine, as the limitations...